NDATOPICALSHAMPOO
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPITROL (chloroxine) is a topical antidandruff shampoo approved in 1976 for the treatment of seborrheic dermatitis and dandruff. It is formulated as a shampoo for scalp application. The mechanism of action involves antimicrobial and anti-inflammatory effects on the scalp.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), brand teams face declining revenue and smaller commercial footprints.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a product in LOE-approaching lifecycle stage, CAPITROL offers limited career growth or advancement opportunities. Professionals assigned to this brand should expect a defensive commercial posture focused on market share retention rather than expansion.
Brand ManagerField Sales Representative
Worked on CAPITROL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.